Autolus Therapeutics - AUTL Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $7.97
  • Forecasted Upside: 30.47%
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$6.11
▲ +0.04 (0.66%)

This chart shows the closing price for AUTL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Autolus Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AUTL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AUTL

Analyst Price Target is $7.97
▲ +30.47% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Autolus Therapeutics in the last 3 months. The average price target is $7.97, with a high forecast of $12.00 and a low forecast of $4.80. The average price target represents a 30.47% upside from the last price of $6.11.

This chart shows the closing price for AUTL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 8 investment analysts is to moderate buy stock in Autolus Therapeutics. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/2/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/1/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/1/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/30/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/28/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/26/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/25/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/24/2024

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/12/2024Needham & Company LLCBoost TargetBuy ➝ Buy$8.00 ➝ $9.00Low
1/22/2024Needham & Company LLCBoost TargetBuy ➝ Buy$7.00 ➝ $8.00Low
12/13/2023The Goldman Sachs GroupBoost TargetNeutral ➝ Neutral$3.20 ➝ $4.80Low
11/29/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$7.00Low
11/15/2023William BlairReiterated RatingOutperformLow
11/9/2023Deutsche Bank AktiengesellschaftInitiated CoverageBuy$10.00Low
10/25/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$7.00Low
8/17/2023Truist FinancialBoost TargetBuy ➝ Buy$6.00 ➝ $9.00Low
5/5/2023Wells Fargo & CompanyLower Target$8.00 ➝ $6.00Low
4/21/2023Needham & Company LLCReiterated RatingBuy$7.00Low
3/27/2023Wells Fargo & CompanyReiterated RatingOverweight$8.00Low
3/17/2023Bryan, Garnier & CoInitiated CoverageBuy$5.00Low
3/8/2023MizuhoLower TargetBuy$18.00 ➝ $12.00Low
3/7/2023Needham & Company LLCReiterated RatingBuy$7.00Low
12/9/2022Needham & Company LLCLower TargetBuy$12.00 ➝ $7.00Low
8/5/2022Needham & Company LLCLower TargetBuy$13.00 ➝ $12.00Low
6/14/2022Truist FinancialLower TargetBuy$13.00 ➝ $11.00High
3/10/2022William BlairReiterated RatingOutperformMedium
12/20/2021HC WainwrightReiterated RatingBuy$11.00Medium
8/2/2021MizuhoReiterated RatingBuy$18.00High
6/14/2021Jefferies Financial GroupUpgradeHold ➝ Buy$6.00 ➝ $12.00Low
5/6/2021Needham & Company LLCLower TargetBuy$26.00 ➝ $21.00Medium
3/16/2021Redburn PartnersReiterated RatingBuy ➝ NeutralHigh
3/10/2021Redburn PartnersDowngradeBuy ➝ NeutralLow
1/29/2021JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$24.00 ➝ $9.00High
1/7/2021Truist FinancialLower Target$30.00 ➝ $15.00N/A
1/7/2021HC WainwrightLower TargetBuy$19.00 ➝ $13.00N/A
1/6/2021MizuhoReiterated RatingBuy$24.00N/A
12/28/2020HC WainwrightReiterated RatingBuy$19.00N/A
12/8/2020Needham & Company LLCReiterated RatingBuy$26.00High
11/25/2020Redburn PartnersInitiated CoverageBuyHigh
9/23/2020William BlairReiterated RatingBuyHigh
9/18/2020Needham & Company LLCReiterated RatingBuy$26.00High
8/6/2020MizuhoReiterated RatingBuy$24.00Low
7/31/2020JPMorgan Chase & Co.Initiated CoverageOverweight$25.00Low
7/22/2020SunTrust BanksInitiated CoverageBuy$38.00High
6/26/2020HC WainwrightReiterated RatingBuy$24.00Low
6/25/2020William BlairReiterated RatingBuyLow
6/19/2020MizuhoBoost TargetBuy$18.00 ➝ $24.00Medium
6/17/2020Jefferies Financial GroupReiterated RatingBuy$27.00Low
6/17/2020William BlairReiterated RatingBuyMedium
6/2/2020William BlairReiterated RatingBuyHigh
6/1/2020Needham & Company LLCInitiated CoverageBuy$26.00High
5/29/2020MizuhoReiterated RatingBuy$18.00High
5/8/2020HC WainwrightReiterated RatingBuyHigh
5/7/2020Needham & Company LLCReiterated RatingBuy$26.00High
4/21/2020MizuhoInitiated CoverageBuy$18.00High
12/9/2019HC WainwrightReiterated RatingBuy$24.00Low
11/8/2019HC WainwrightReiterated RatingBuyHigh
11/7/2019William BlairReiterated RatingBuyHigh
9/23/2019Needham & Company LLCInitiated CoverageBuy$26.00 ➝ $26.00Low
9/12/2019HC WainwrightReiterated RatingBuy$24.00Low
9/3/2019William BlairReiterated RatingBuyLow
5/17/2019HC WainwrightReiterated RatingBuy ➝ Buy$45.00 ➝ $41.00Low
4/3/2019William BlairReiterated RatingBuyLow
(Data available from 2/24/2019 forward)

News Sentiment Rating

0.44 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/29/2023
  • 3 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/28/2023
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
9/27/2023
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/27/2023
  • 2 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/26/2023
  • 5 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
12/26/2023
  • 3 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
1/25/2024
  • 7 very positive mentions
  • 21 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
2/24/2024

Current Sentiment

  • 7 very positive mentions
  • 21 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Autolus Therapeutics logo
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
Read More

Today's Range

Now: $6.11
Low: $5.93
High: $6.20

50 Day Range

MA: $6.34
Low: $5.18
High: $7.29

52 Week Range

Now: $6.11
Low: $1.61
High: $7.45

Volume

1,650,649 shs

Average Volume

2,177,161 shs

Market Capitalization

$1.06 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.92

Frequently Asked Questions

What sell-side analysts currently cover shares of Autolus Therapeutics?

The following Wall Street research analysts have issued research reports on Autolus Therapeutics in the last year: Bryan, Garnier & Co, Deutsche Bank Aktiengesellschaft, Mizuho, Needham & Company LLC, The Goldman Sachs Group, Inc., Truist Financial Co., Wells Fargo & Company, and William Blair.
View the latest analyst ratings for AUTL.

What is the current price target for Autolus Therapeutics?

7 Wall Street analysts have set twelve-month price targets for Autolus Therapeutics in the last year. Their average twelve-month price target is $7.97, suggesting a possible upside of 30.5%. Mizuho has the highest price target set, predicting AUTL will reach $12.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $4.80 for Autolus Therapeutics in the next year.
View the latest price targets for AUTL.

What is the current consensus analyst rating for Autolus Therapeutics?

Autolus Therapeutics currently has 1 hold rating and 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for AUTL.

What other companies compete with Autolus Therapeutics?

How do I contact Autolus Therapeutics' investor relations team?

Autolus Therapeutics' physical mailing address is FOREST HOUSE 58 WOOD LANE WHITE CITY, LONDON X0, W12 7RZ. The company's listed phone number is 442038296230 and its investor relations email address is [email protected]. The official website for Autolus Therapeutics is www.autolus.com. Learn More about contacing Autolus Therapeutics investor relations.